2.3. Determination of the Biomarkers
Tumor
TUMORIGENICITY, TUMOR
ICAM-1 was analysed using kit number DY720, Human Adiponectin (DY1065), Leptin (DY398), SCF (DY255), OPG (DY805), Cathepsin S (DY1183), Endostatin (DY1098), Matrix Metallo Proteinase-1(MMP-1) (DY901), Soluble suppression of Tumorigenicity 2 protein (ST-2)/IL-33 R (DY523B), and Tumor necrosis-factor-like Weak inducer of Apoptosis (TWEAK) (DY1090), using commercially available sandwich enzyme-linked immunosorbent assay kit (ELISA) (R&D Systems, Minneapolis, MN, USA). The assays had a total coefficient of variation of approximately 6%. Plasma copeptin was measured on the Kryptor Compact platform (BRAHMS Gmbh, Hennigsdorf, Germany). The interassay CVs are <15% at 20 pmol/L, <13% for 20–50 pmol/L and <8% for concentrations >50 pmol/L according to previous validation [The persons performing the measurements were blinded as to the purpose of the study and had no knowledge of the clinical data.